Envestnet Portfolio Solutions Inc. Has $518,000 Stake in argenex SE $ARGX

Envestnet Portfolio Solutions Inc. boosted its position in shares of argenex SE (NASDAQ:ARGX) by 4.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 940 shares of the company’s stock after buying an additional 36 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in argenex were worth $518,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ARGX. WPG Advisers LLC acquired a new stake in shares of argenex in the 1st quarter valued at approximately $37,000. Golden State Wealth Management LLC acquired a new stake in shares of argenex in the 1st quarter valued at approximately $44,000. Brooklyn Investment Group boosted its stake in shares of argenex by 102.7% in the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of argenex in the 1st quarter valued at approximately $62,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

Shares of NASDAQ ARGX opened at $834.75 on Wednesday. The company has a 50 day simple moving average of $742.84 and a 200 day simple moving average of $639.72. The firm has a market cap of $51.39 billion, a PE ratio of 42.81, a price-to-earnings-growth ratio of 0.91 and a beta of 0.46. argenex SE has a 1 year low of $510.05 and a 1 year high of $855.46.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, research analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARGX shares. Stifel Nicolaus set a $882.00 price target on shares of argenex in a research note on Thursday, September 18th. Guggenheim restated a “buy” rating and issued a $1,070.00 price target on shares of argenex in a research note on Thursday, September 18th. Wells Fargo & Company raised their price target on shares of argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Truist Financial raised their price target on shares of argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Finally, Morgan Stanley raised their price objective on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $817.53.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.